Phenibut: Evidence, Documented Harms and Legal Status

Phenibut is a prescription medicine in Russia and a legal-to-possess but unapproved substance in the United States. In the US the FDA says it is not a lawful dietary ingredient. The clinical evidence for benefit is old, mostly Russian and thin, while the record of intoxication, dependence and withdrawal is large enough to fill several systematic reviews.

Key points

• Phenibut (beta-phenyl-GABA) was developed in Russia in the 1960s and is still sold there as a prescription tablet [1][2][11].
• We found no modern randomized, placebo-controlled trial of phenibut. The clinical literature is mostly Russian-language, and we opened only abstracts and titles of it [1][14].
• Published reviews of case reports describe intoxication, dependence and a withdrawal syndrome that often needs hospital care [3][4][5][6].
• The FDA states phenibut “does not meet the statutory definition of a dietary ingredient” [10]. Its legal status elsewhere varies and we could not verify several countries.
• Two X tier lists rank it very low (“extremely cope”, “F tier”). Our verdict on both: partly supported, for reasons that differ from the posters’ framing.

What phenibut is

Phenibut is a derivative of GABA, the main inhibitory neurotransmitter, with a phenyl ring added. A 2001 review in CNS Drug Reviews describes it as introduced in Russia in the 1960s as a “tranquilizer and nootropic”, acting mainly as a GABA-B receptor agonist and, to a lesser degree, at GABA-A receptors. Its activity resembles that of baclofen [1]. A 2024 review by Penzak and Bulloch also dates its first synthesis to Russia in the early 1960s [2]. Gurley and Koturbash add activity at beta-phenethylamine receptors in their 2024 toxicology review [3].

Other names include phenibut HCl, Phenigam, fenibut and PGaba [10][11].

Where it is a medicine

Russian drug register RLS lists several phenibut products. The entry for 250 mg tablets, held by Olainfarm (Latvia) with a representative in Moscow, is marked as dispensed by prescription. Its listed uses include anxiety-neurotic and asthenic states, stuttering and tics in children, insomnia in the elderly, vestibular dizziness, motion sickness prevention and, as part of complex therapy, alcohol withdrawal. The page was updated 30 September 2026 and its instruction approved 26 August 2025. It lists liver toxicity with prolonged high-dose use as an adverse reaction. We did not see a dependence warning on that page [11].

We did not verify its status in Ukraine, Belarus, Georgia or other post-Soviet states, and we did not check the register of Latvia or any other EU member state.

What the clinical evidence shows

Lapin’s 2001 review is a narrative summary of mostly Soviet and Russian work claiming anxiolytic and nootropic effects, and it reports uses in Russian practice for tension, anxiety, sleep problems and asthenia. Its abstract gives no trial sizes or effect numbers [1].

When we searched Europe PMC for phenibut or fenibut records tagged as clinical trials or randomized, the human hits were Russian-language reports with English titles, among them a 2015 paper on medicines for situational anxiety under psycho-emotional stress, a 2011 bioequivalence study of two phenibut products, and 1997-1998 studies of heat resistance in volunteers [14]. We read titles only. We could not assess their design, size or funding, and none of them tests phenibut against placebo for anxiety or cognition in a modern trial. Absence from this search is not proof that no such trial exists, and we did not search Russian-language registries.

Most of the rest of the results were animal studies of anxiety models [14].

Documented harms

Case reviews. Four reviews have pooled published case reports:

Review	Cases	What it reported
Weleff et al., J Addict Med, 2023 [4]	62 cases from 36 studies	Mean age about 31, 81% male, most obtained it online, about 63% used other addictive substances; toxicity often meant altered mental status and intubation
Feldman et al., Clin Toxicol, 2023 [5]	25 reports	All male, median age 30; withdrawal often progressive; 44% admitted to intensive care; similar outcomes in phenibut-only and polysubstance use
Penzak and Bulloch, J Clin Pharmacol, 2024 [2]	29 withdrawal cases	Authors expect cases to rise while phenibut stays legal and advise taking a detailed medication history
Stewart et al., Cureus, 2024 [6]	15 case reports, 2010 to October 2023	Mean age about 32, 87% male, 60% presented to an emergency department

Case reports over-represent severe outcomes, so they cannot give a rate of harm. Funding or conflicts were not stated in the records we read, except that Gurley and Koturbash report US National Institutes of Health grants [3].

Poison-centre data. The CDC’s MMWR (4 September 2020) analysed National Poison Data System calls: 1,320 phenibut exposures from 2009 to 2019. Of these, 12.6% had major effects, 6.2% (80 cases) had coma, and three deaths were reported, one of them with phenibut as the only substance. Exposures rose sharply after 2015, a period when poison centres began using “phenibut” as a search term. The authors say the cause of the increase is unknown. They note exposures are not lab-confirmed, since routine urine drug screens do not detect phenibut [7].

A Minnesota study (McCabe et al., Am J Emerg Med, 2019) of poison-centre calls from 2000 to 2018 found 56 phenibut exposures, 48 of them in the final five years. More than half had central nervous system effects, 11 patients (19.6%) were intubated, and there were no deaths [8].

A German review (Bonnet et al., Dtsch Arztebl Int, 2024) saw a milder picture in its own data: the Nord poison centre received 17 phenibut inquiries from 2008 to 2022, most intoxications were mild, and no coma or respiratory depression occurred. The authors write that no phenibut deaths had been published in Western Europe, and warn that combining it with opiates may raise that risk [9].

Withdrawal. The reviews describe a withdrawal syndrome in people who used it regularly, including cases with delirium and intensive-care admission [4][5]. It is a medical problem. Anyone physically dependent on phenibut needs supervised medical care, and this article does not describe a treatment approach.

Regulatory status

Country	Status	Source and date
Russia	Prescription medicine	RLS entry, updated 30 Sep 2026 [11]
United States	Not FDA-approved as a drug; legal to possess; FDA says it is not a dietary ingredient	MMWR, 4 Sep 2020 [7]; FDA page current as of 12 Jul 2023 [10]
Germany	Described by clinical authors as an illegal food supplement; legal basis not checked by us	Bonnet et al., 2024 [9]
Australia	Not verified: the TGA decision documents timed out when we tried to open them
UK	Not checked
EU level, other states	Not checked

United States. The FDA’s ingredient page lists warning letters dated 10 April 2019 to Atomixx, Evol Nutrition Associates and NeuroScience Solutions. It also records a 2 June 2023 permanent injunction against a seller trading as Chill6 in the US District Court for Massachusetts, which the FDA alleges sold products containing phenibut HCl as an unsafe food additive. The FDA calls its page incomplete as a list of actions [10]. The legal objection concerns the ingredient category. The page does not say that the letters found a specific safety defect, and the MMWR authors add only that the agency has not approved phenibut as a pharmaceutical [7][10].

“Research use only” labelling does not change this. A label does not alter what a substance is under the law, and we did not find an FDA statement addressing research-labelled phenibut.

Gaps

We found no controlled data on how often regular users become dependent, no long-term safety studies in healthy adults, no pregnancy data, and no information on interactions beyond case reports of co-use with other sedatives or opioids [3][9]. Poison-centre counts depend on how often a product is named. Western case series come largely from men in their thirties who bought it online, so they say little about the Russian prescription population [4][6].

What the source posts claim

The tier-list placements below were read from the images by the Peptilyze team on 2026-11-08; we did not open X itself, and the lists give no reasons.

@Hoostethics, “ranking the most cope supplements” (2026-10-15) puts phenibut in “extremely cope”, beside ashwagandha, cannabis, finasteride, SSRIs and diazepam [12]. If “cope” means an ineffective placebo-like supplement, that is not supported: phenibut has strong, documented pharmacological effects, including intoxication and withdrawal [4][5]. If it means a poor substitute for treating anxiety, partly supported: its benefit evidence is old and sparse, and the harm record is substantial [1][7]. Verdict: partly supported.

@dex7official, “The only true cognitive enhancement tier list” (2026-10-20) puts phenibut in F, with creatine, cannabis, BPC-157 and pinealon [13]. We found no controlled evidence that phenibut enhances cognition in healthy adults [1][14], so a low ranking is consistent with the record. The list also places pregabalin, insulin and creatine in F and methamphetamine in S, and gives no criteria, so the ranking tells a reader little. Verdict: partly supported; we did not find evidence for or against cognitive enhancement, and the safety record is the stronger reason to rank it low.

Frequently asked questions

Is phenibut approved as a medicine? In Russia it is a prescription tablet, according to the RLS register [11]. In the US it is not FDA-approved [7]. We did not verify its status in the UK, the EU as a whole, or most other countries.

Is phenibut legal as a dietary supplement in the US? The FDA’s position is that it does not meet the definition of a dietary ingredient, so supplements declaring it are misbranded [10]. Possession is not criminalised federally [7].

Does phenibut cause dependence? Published case reports and systematic reviews document dependence and a withdrawal syndrome, with some patients needing intensive care [4][5]. These are case reports, so they do not show how common it is. Withdrawal needs medical care.

Is there good evidence that phenibut helps anxiety? We found none in the form of a modern randomized, placebo-controlled trial. The supportive literature is largely Russian and old, and we read only titles or abstracts [1][14].

Sources

1. Lapin I, “Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug”, CNS Drug Reviews 7(4):471-481 (2001). PMID 11830761, read as an abstract via Europe PMC.
2. Penzak SR, Bulloch M, “Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal”, Journal of Clinical Pharmacology 64(6):652-671 (2024). PMID 38339875, read as an abstract via Europe PMC.
3. Gurley BJ, Koturbash I, “Phenibut: A drug with one too many ‘buts’”, Basic & Clinical Pharmacology & Toxicology 135(4):409-416 (2024). PMID 39197876, abstract via Europe PMC.
4. Weleff J et al., “Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review”, Journal of Addiction Medicine 17(4):407-417 (2023). PMID 37579098, abstract via Europe PMC.
5. Feldman R et al., “A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal”, Clinical Toxicology 61(11):941-951 (2023). PMID 38112312, abstract via Europe PMC.
6. Stewart C et al., “A Systematic Review of Phenibut Withdrawals”, Cureus 16(9):e68775 (2024). PMID 39376891, abstract via Europe PMC.
7. Graves JM, Dilley J, Kubsad S, Liebelt E, “Notes from the Field: Phenibut Exposures Reported to Poison Centers, United States, 2009-2019”, CDC MMWR 69(35):1227-1228 (4 Sep 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6935a5.htm
8. McCabe DJ et al., “Phenibut exposures and clinical effects reported to a regional poison center”, American Journal of Emergency Medicine 37(11):2066-2071 (2019). PMID 30878413, abstract via Europe PMC.
9. Bonnet U et al., “Phenibut: An Illegal Food Supplement With Psychotropic Effects and Health Risks”, Deutsches Ärzteblatt International 121(7):222-227 (2024). PMID 38377332, abstract via Europe PMC.
10. US Food and Drug Administration, “Phenibut in Dietary Supplements” (content current as of 12 Jul 2023). https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements
11. RLS (Russian drug register), “Фенибут” tablets 250 mg (updated 30 Sep 2026; instruction approved 26 Aug 2025). https://www.rlsnet.ru/drugs/fenibut-5083
12. @Hoostethics, “ranking the most cope supplements” (15 Oct 2026). https://x.com/Hoostethics/status/2110728908735979632 (placement read from the tier-list image transcription made by Peptilyze on 8 Nov 2026; X itself was not opened).
13. @dex7official, “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” (20 Oct 2026). https://x.com/dex7official/status/2112691493261484516 (same transcription note).
14. Europe PMC search results for phenibut/fenibut with clinical-trial and anxiety terms, run 8 Nov 2026. https://www.ebi.ac.uk/europepmc/ (titles and abstracts only; includes Ivanov and Bondarenko 2015, Zhezlova et al. 2011, Makarov et al. 1997-1998).

This article is information, not medical advice.